{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:22:46Z","timestamp":1783506166722,"version":"3.55.0"},"reference-count":68,"publisher":"MDPI AG","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11,1]]},"abstract":"\n \n Background<\/jats:title>\n Toenail onychomycosis is a common disease with limited treatment options; treatment failure and relapse are frequently encountered. Many patients experience long-standing disease affecting multiple toenails, with substantial discomfort and pain. Although some patients might prefer a topical therapy, efficacy with ciclopirox nail lacquer has been disappointing.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Efinaconazole topical solution, 10% is the first topical triazole antifungal agent specifically developed for the treatment of onychomycosis. This paper reviews the preclinical and clinical data on efinaconazole topical solution, 10%.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Efinaconazole has a broad spectrum of antifungal activity in vitro and is more potent than ciclopirox against common onychomycosis pathogens. It has a more optimal keratin affinity than ciclopirox, and it exhibits significantly greater in vivo activity owing to its superior nail penetration. Mycologic cure rates at week 52 were 55.2% (study 1) and 53.4% (study 2) with efinaconazole topical solution, 10% compared with 16.8% and 16.9%, respectively, with vehicle (P<.001 for both). In addition, efinaconazole is well tolerated.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Efinaconazole topical solution, 10% may likely become a preferred topical agent for the management of mild-to-moderate onychomycosis.<\/jats:p>\n <\/jats:sec>","DOI":"10.7547\/8750-7315-104.6.568","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T17:30:08Z","timestamp":1418751008000},"page":"568-573","source":"Crossref","is-referenced-by-count":2,"title":["Efinaconazole Topical Solution, 10%"],"prefix":"10.3390","volume":"104","author":[{"given":"Richard A.","family":"Pollak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"ref681","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1468-3083.2011.04373.x","article-title":"Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs","volume":"27","author":"Elewski","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"491","DOI":"10.7547\/87507315-90-10-491","article-title":"The dermatopharmacologic profile of ciclopirox 8% nail lacquer","volume":"90","author":"Bohn","year":"2000","journal-title":"JAPMA"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.1999.00008.x","article-title":"LION Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis: Lamisil vs itraconazole in onychomycosis","volume":"141","author":"Sigurgeirsson","year":"1999","journal-title":"Br J Dermatol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2011.02.038","article-title":"Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment","volume":"66","author":"Gupta","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11046-008-9110-7","article-title":"Antifungal resistance mechanisms in dermatophytes","volume":"166","author":"Martinez-Rossi","year":"2008","journal-title":"Mycopathologia"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7547\/87507315-90-10-495","article-title":"Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States","volume":"90","author":"Gupta","year":"2000","journal-title":"JAPMA"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2011.11.001","article-title":"Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment","volume":"125","author":"Pfaller","year":"2012","journal-title":"Am J Med"},{"key":"ref691","article-title":"Development of an optimal formulation for efinaconazole a novel antifungal agent for the treatment of onychomycosis by topical application","author":"Bhatt","journal-title":"Poster presented at: 71st Annual Meeting of the American Academy of Dermatology; March 1\u20135, 2013; Miami Beach, FL"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003495-199958020-00005","article-title":"Management of onychomycoses","volume":"58","author":"Niewerth","year":"1999","journal-title":"Drugs"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7547\/87507315-92-5-272","article-title":"Treatment of dermatophyte toenail onychomycosis in the United States: a pharmacoeconomic analysis","volume":"92","author":"Gupta","year":"2002","journal-title":"JAPMA"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1439-0507.2006.01351.x","article-title":"Onychomycosis","volume":"50","author":"Seebacher","year":"2007","journal-title":"Mycoses"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3810\/pgm.1998.02.359","article-title":"Common dermatophyte infections: a simple diagnostic test and current management","volume":"103","author":"Crissey","year":"1998","journal-title":"Postgrad Med"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase 3 multicenter, randomized, double-blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref651","first-page":"815","article-title":"The efficacy and safety of efinaconazole 10% solution in the treatment of mild to moderate onychomycosis: a pooled anaylsis of two phase 3 randomized trials","volume":"13","author":"Gupta","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.02063-12","article-title":"Mechanism of antifungal action of efinaconazole, a novel triazole agent","volume":"57","author":"Tatsumi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.02056-12","article-title":"Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis","volume":"57","author":"Jo Siu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1128\/AAC.02703-13","article-title":"In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal","volume":"58","author":"Iwata","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1468-3083.2009.03164.x","article-title":"An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis","volume":"23","author":"Baran","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00128071-200405030-00002","article-title":"Assessing treatment outcomes in toenail onychomycosis clinical trials","volume":"5","author":"Werschler","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.1999.00008.x","article-title":"LION Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis: Lamisil vs itraconazole in onychomycosis","volume":"141","author":"Sigurgeirsson","year":"1999","journal-title":"Br J Dermatol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase 3 multicenter, randomized, double-blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0190-9622(99)70047-2","article-title":"The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life","volume":"1","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002512-200724040-00003","article-title":"Onychomycosis in the elderly: drug treatment options","volume":"24","author":"Loo","year":"2007","journal-title":"Drugs Aging"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00128071-200405030-00002","article-title":"Assessing treatment outcomes in toenail onychomycosis clinical trials","volume":"5","author":"Werschler","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.02056-12","article-title":"Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis","volume":"57","author":"Jo Siu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3810\/pgm.1998.02.359","article-title":"Common dermatophyte infections: a simple diagnostic test and current management","volume":"103","author":"Crissey","year":"1998","journal-title":"Postgrad Med"},{"key":"ref01","first-page":"11","article-title":"Advances in the diagnosis and treatment of onychomycosis","volume":"34","author":"Scher","year":"1998","journal-title":"Hosp Med"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","article-title":"Onychomycosis: treatment, quality of life, and economic issues","volume":"1","author":"Elewski","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0190-9622(03)02117-0","article-title":"Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002","volume":"50","author":"Foster","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002512-200724040-00003","article-title":"Onychomycosis in the elderly: drug treatment options","volume":"24","author":"Loo","year":"2007","journal-title":"Drugs Aging"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.47.1.82-86.2003","article-title":"Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine","volume":"47","author":"Mukherjee","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","article-title":"Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref71","first-page":"875","article-title":"Today's treatments options for onychomycosis","volume":"8","author":"Iorizzo","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7547\/87507315-92-5-272","article-title":"Treatment of dermatophyte toenail onychomycosis in the United States: a pharmacoeconomic analysis","volume":"92","author":"Gupta","year":"2002","journal-title":"JAPMA"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1468-3083.2011.04373.x","article-title":"Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs","volume":"27","author":"Elewski","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1128\/AAC.00111-14","article-title":"Efinaconazole: low keratin affinity contributes to nail penetration and fungicidal activity in topical onychomycosis treatment","volume":"58","author":"Sugiura","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0190-9622(99)70047-2","article-title":"The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life","volume":"1","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","article-title":"Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.47.1.82-86.2003","article-title":"Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine","volume":"47","author":"Mukherjee","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2009.04.062","article-title":"Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents","volume":"62","author":"Piraccini","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","article-title":"Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1439-0507.2006.01351.x","article-title":"Onychomycosis","volume":"50","author":"Seebacher","year":"2007","journal-title":"Mycoses"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.45.5.1493-1499.2001","article-title":"In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs","volume":"45","author":"Tatsumi","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1468-3083.2009.03164.x","article-title":"An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis","volume":"23","author":"Baran","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7547\/87507315-90-10-495","article-title":"Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States","volume":"90","author":"Gupta","year":"2000","journal-title":"JAPMA"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.02063-12","article-title":"Mechanism of antifungal action of efinaconazole, a novel triazole agent","volume":"57","author":"Tatsumi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.2310\/7750.2006.00056","article-title":"Prevalence and epidemiology of onychomycosis","volume":"10","author":"Vender","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11046-008-9110-7","article-title":"Antifungal resistance mechanisms in dermatophytes","volume":"166","author":"Martinez-Rossi","year":"2008","journal-title":"Mycopathologia"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.45.5.1493-1499.2001","article-title":"In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs","volume":"45","author":"Tatsumi","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2011.02.038","article-title":"Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment","volume":"66","author":"Gupta","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref291","first-page":"815","article-title":"The efficacy and safety of efinaconazole 10% solution in the treatment of mild to moderate onychomycosis: a pooled anaylsis of two phase 3 randomized trials","volume":"13","author":"Gupta","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","article-title":"Onychomycosis: treatment, quality of life, and economic issues","volume":"1","author":"Elewski","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"ref641","first-page":"239","article-title":"Onychomycosis: Burden of illness and successful treatment with a new topical antifungal","volume":"6","author":"Young","year":"2014","journal-title":"J Dermatol Nurs Assoc"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.2310\/7750.2006.00056","article-title":"Prevalence and epidemiology of onychomycosis","volume":"10","author":"Vender","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"ref431","first-page":"875","article-title":"Today's treatments options for onychomycosis","volume":"8","author":"Iorizzo","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","article-title":"Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1128\/AAC.02703-13","article-title":"In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal","volume":"58","author":"Iwata","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"491","DOI":"10.7547\/87507315-90-10-491","article-title":"The dermatopharmacologic profile of ciclopirox 8% nail lacquer","volume":"90","author":"Bohn","year":"2000","journal-title":"JAPMA"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2009.04.062","article-title":"Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents","volume":"62","author":"Piraccini","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref361","first-page":"11","article-title":"Advances in the diagnosis and treatment of onychomycosis","volume":"34","author":"Scher","year":"1998","journal-title":"Hosp Med"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1128\/AAC.00111-14","article-title":"Efinaconazole: low keratin affinity contributes to nail penetration and fungicidal activity in topical onychomycosis treatment","volume":"58","author":"Sugiura","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref281","first-page":"239","article-title":"Onychomycosis: Burden of illness and successful treatment with a new topical antifungal","volume":"6","author":"Young","year":"2014","journal-title":"J Dermatol Nurs Assoc"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003495-199958020-00005","article-title":"Management of onychomycoses","volume":"58","author":"Niewerth","year":"1999","journal-title":"Drugs"},{"key":"ref331","article-title":"Development of an optimal formulation for efinaconazole a novel antifungal agent for the treatment of onychomycosis by topical application","author":"Bhatt","journal-title":"Poster presented at: 71st Annual Meeting of the American Academy of Dermatology; March 1\u20135, 2013; Miami Beach, FL"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2011.11.001","article-title":"Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment","volume":"125","author":"Pfaller","year":"2012","journal-title":"Am J Med"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0190-9622(03)02117-0","article-title":"Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002","volume":"50","author":"Foster","year":"2004","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/104\/6\/568\/1604933\/8750-7315-104_6_568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/104\/6\/568\/1604933\/8750-7315-104_6_568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:12:51Z","timestamp":1783505571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/104\/6\/568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,1]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11,1]]}},"URL":"https:\/\/doi.org\/10.7547\/8750-7315-104.6.568","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,1]]}}}